Clincosm LogoSign in Get a demo

HEPEPID: Epidemiology of Hepatitis B, C and Delta in Reunion Island

Sponsor
Centre Hospitalier Universitaire de la Réunion (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT03362866
Collaborator
(none)
2,000
Enrollment
51
Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

Viral hepatitis B, C and Δ represent a global public health problem for which France was very early mobilized. Despite this, in its foreword, the Dhumeaux report on "Management of people infected with hepatitis B or hepatitis C viruses" identifies a residual area of weakness in this care that is the incomplete regional epidemiological data in the Overseas Territories. The specific ethno-socio-cultural characteristics of these territories make it difficult to transpose data from the mainland France. This study aims at improving our knowledge on the characteristics of patients with hepatitis B, C and Δ in Reunion Island, their follow-up, their evolution and complications.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    2000 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Epidemiology of Hepatitis B, C and Delta in Reunion Island
    Anticipated Study Start Date :
    Jan 1, 2019
    Anticipated Primary Completion Date :
    Apr 1, 2023
    Anticipated Study Completion Date :
    Apr 1, 2023

    Outcome Measures

    Primary Outcome Measures

    1. Number of patients with hepatitis B, C and Δ in Reunion [Up to 5 years]

      Hepatitis diagnosis will be made according to the ongoing guidelines in France (referred by the National AIDS and Hepatitis Research Agency (ANRS)

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    Major patient

    • with confirmed HBsAg and / or anti HCV positive Ab

    • residing in Reunion Island

    • followed in one of the participating centers

    Exclusion Criteria:

    • Patient carrying isolated anti HBc antibodies

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Centre Hospitalier Universitaire de la Réunion

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Centre Hospitalier Universitaire de la Réunion
    ClinicalTrials.gov Identifier:
    NCT03362866
    Other Study ID Numbers:
    • 2016/CHU/14
    First Posted:
    Dec 5, 2017
    Last Update Posted:
    Sep 5, 2018
    Last Verified:
    Sep 1, 2018
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Hepatitis A
    Hepatitis C
    Hepatitis B
    Hepatitis D
    Hepatitis

    Study Results

    No Results Posted as of Sep 5, 2018